Sarah Bennett
There have been reports of herpes zoster, or shingles, in patients following the Shingrix vaccination. This reactivation of the varicella zoster virus (VZV) can cause painful skin lesions and other symptoms that may last for weeks or months. While the vaccine is intended to prevent this disease, some patients have tested positive for VZV or herpes-simplex viruses (HSV) following immunization. Additionally, there have been reports of herpesvirus activation, including VZV and HSV reactivation, following COVID-19 vaccination with Moderna and Pfizer-BioNTech vaccines.
| Characteristics | Values |
|---|---|
| Herpes Zoster Vaccine | Approved for clinical use among older adults by the FDA |
| Has been tested in large populations | |
| Does not cause positive PCR or antigen test results | |
| May cause positive antibody test results | |
| Can cause side effects such as a generalized rash and bilateral retinal necrosis |
Explore related products
What You'll Learn
Herpes-zoster vaccination in immunocompetent people aged ≥ 50 years
The CDC recommends two doses of the recombinant zoster vaccine (RZV), Shingrix, for immunocompetent adults aged ≥ 50 years for the prevention of herpes zoster, or shingles. The second dose should be administered 2-6 months after the first dose. This recommendation was made official CDC policy in January 2018.
The ACIP considers people born in the United States prior to 1980 to be immune to varicella. Hence, when vaccinating immunocompetent adults aged ≥ 50 years, there is no need to screen for a history of varicella or to conduct laboratory testing for serologic evidence of prior varicella.
In a German study, patients with skin manifestations after HZ vaccination were tested for VZV by polymerase chain reaction (PCR). The majority tested negative for VZV, and some were positive for herpes-simplex virus type 1 or 2. The lesions occurred mostly in the first weeks after the first dose of Shingrix and shortly after the second. The virus detected in the patients was not a vaccine strain.
Several studies have been conducted on the immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults aged ≥ 50 years. One study investigated the co-administration of the vaccine with a seasonal influenza vaccine, while others looked at co-administration with the 23-valent pneumococcal polysaccharide vaccine, a tetanus-diphtheria-pertussis vaccine, and the 13-valent pneumococcal conjugate vaccine.
Vaccine Requirements for US Re-entry from Peru
You may want to see also
Explore related products
The herpes zoster vaccine with an active virus
Herpes zoster, also known as shingles, is a painful rash illness caused by the varicella-zoster virus (VZV). The illness occurs when the virus that causes chickenpox stays dormant in the body and reactivates years later. The risk of contracting herpes zoster increases with age.
The zoster vaccine live (Zostavax) was a live-attenuated varicella-zoster virus (VZV) vaccine that was previously used to prevent herpes zoster. However, as of November 18, 2020, Zostavax is no longer available for use in the United States due to its reduced effectiveness over time.
The recombinant zoster vaccine (RZV), Shingrix, is currently recommended by the CDC for the prevention of herpes zoster and related complications. Shingrix is an adjuvanted VZV glycoprotein E (gE) subunit vaccine that has been shown to be effective in preventing shingles, especially in older adults. It is given as a two-dose series, with the second dose administered 2-6 months after the first.
While Shingrix is generally well-tolerated, some side effects have been reported, such as pain and Guillain-Barré syndrome (GBS), a rare nervous system disorder. It is important to note that Shingrix does not cause a positive test result for VZV, as the vaccine does not contain the live virus. However, some patients have reported zoster-like skin reactions following immunisation with Shingrix, and a small number of patients have tested positive for the herpes-simplex virus (HSV) type 1 or 2.
The Truth About Luke Perry's Death and Pneumonia Vaccine
You may want to see also
Explore related products
The live attenuated zoster vaccine
Zostavax was first approved by the Food and Drug Administration in May 2006 and was the first vaccine available for shingles prevention. However, since October 2017, it has been replaced as the first-line therapy by Shingrix, a recombinant zoster vaccine that is more effective and has longer-lasting protection.
The efficacy of Zostavax in preventing shingles is highest in patients aged 60 to 69 and decreases with increasing age. It reduces the risk of shingles by 51% and the risk of post-herpetic neuralgia (nerve pain caused by shingles) by 67%. The protection offered by Zostavax wanes over time, typically lasting around five years.
Zostavax is contraindicated in individuals with suppressed immune systems, who are already at higher risk of developing shingles. This includes people living with HIV or cancer, those taking immunosuppressants, and transplant recipients. The vaccine is generally well-tolerated, but side effects may occur, and individuals should seek medical advice if they experience any adverse reactions. It is important to note that Zostavax will not treat an active shingles infection or nerve pain associated with shingles.
In summary, the live attenuated zoster vaccine, Zostavax, is a valuable tool in preventing shingles in older adults with healthy immune systems. However, it has been largely superseded by the more effective and durable recombinant vaccine, Shingrix, for which Zostavax is now a second-line therapy.
Boosters and Vaccines: What's the Difference?
You may want to see also
Explore related products
$24.98 $34.23
Herpes zoster or shingles
Shingles, also known as herpes zoster, is a viral infection that causes a painful rash. It is caused by the varicella-zoster virus (VZV), the same virus that causes chickenpox. After an individual has had chickenpox, the virus remains dormant in the body and can reactivate later in life, causing shingles. Shingles typically appears as a stripe of blisters on one side of the torso, but it can also develop on the face, genitals, ears, or other parts of the body. It is not life-threatening, but it can be very painful, and the most common complication is postherpetic neuralgia, which can cause long-lasting nerve pain.
Shingles and herpes are two different conditions, but they share some similarities. Both conditions can cause blistering rashes, and they are caused by viruses from the herpesvirus family. However, shingles are caused by the varicella-zoster virus, while herpes is caused by the herpes simplex virus (HSV). The appearance of the rashes also differs, with herpes typically affecting the face, mouth, genitals, or rectum, while shingles usually affects the torso or waistline. Additionally, herpes is a sexually transmitted infection, whereas shingles is not.
The varicella-zoster virus can spread through direct skin-to-skin contact with fluid from the blisters or by breathing in particles from the blisters. If someone who has not had chickenpox before comes into contact with the virus, they will develop chickenpox rather than shingles. Therefore, it is important to avoid physical contact with anyone who has not had chickenpox or received the chickenpox vaccine until the shingles blisters have scabbed over and are no longer contagious.
Vaccines can help lower the risk of developing shingles, and early treatment may shorten the infection and reduce the chances of complications. Some people may also experience symptoms such as nerve pain and discolouration before the rash appears. It is important to see a healthcare provider if you have any symptoms of shingles, even if you do not have a rash, as early diagnosis and treatment can improve outcomes.
Vaccinated and Tested: What's the Deal?
You may want to see also
Explore related products
The reactivation of the herpes zoster virus
The varicella-zoster virus (VZV) causes chickenpox, which can be severe in immunocompromised individuals, infants, and adults. After the initial infection, the virus remains dormant in the nervous system, specifically in the ganglia of the sensory nervous system, and can be reactivated after several years or even decades. This reactivation is caused by a decline in the cellular immune response and is more likely to occur in old age, or due to circumstances such as hard work, steroid use, or malignancies.
Shingles, also known as herpes zoster, is caused by the reactivation of the varicella-zoster virus. It affects tissues innervated by the involved neurons and can lead to inflammation, cell death, and persistent radicular pain (postherpetic neuralgia). Shingles occur mainly in older individuals who have had chickenpox earlier in life. The reactivation of the varicella-zoster virus can also lead to complications such as myelitis, cranial nerve palsies, meningitis, stroke (vasculopathy), retinitis, and gastroenterological infections like ulcers, pancreatitis, and hepatitis.
It is important to distinguish between the reactivation of the herpes zoster virus and the vaccination for herpes zoster. The vaccination, introduced in 2013 for individuals aged 70-79 in the UK, is meant to prevent shingles by reducing the risk of virus reactivation. Two types of vaccines are available: the recombinant herpes zoster vaccine (RZV) and the live attenuated zoster vaccine (ZVL). A global systematic review and meta-analysis found that vaccination with either of these vaccines was associated with a significantly lower risk of heart attack and stroke in adults aged 18 and above, as well as adults aged 50 and older.
In rare cases, there have been reports of suspected herpes zoster or zoster-like skin reactions following immunization with the recombinant zoster vaccine. However, it is important to note that these skin manifestations are not due to the vaccine strain of the virus. Most patients with skin lesions after vaccination tested negative for VZV, and the few who tested positive were not unexpected as shingles can occur even after full immunization.
Vaccination Status: Attending Olivia Rodrigo's Concert
You may want to see also
Frequently asked questions
Yes, there have been reports of patients testing positive for the herpes-simplex virus type 1 or 2 after receiving the Shingrix vaccination. However, the virus detected in these patients was not a vaccine strain.
The herpes zoster vaccine, also known as the shingles vaccine, is a vaccine that contains a live attenuated virus. It is used to prevent the reactivation of the varicella-zoster virus (VZV) or chickenpox in older adults.
The most common side effect of the herpes zoster vaccine is a generalized body rash. Other possible side effects include bilateral retinal necrosis, acute retinal necrosis, and ocular symptoms. In rare cases, the vaccine can cause health damage beyond the customary level of vaccination side effects.
